Geneos cancer vaccine shrinks liver tumors in small trial reut.rs/3xvyl3C

#1/8 Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 (pembro) in 2L #HCC presented at #AACR2024 & published in Nature Medicine
➡️nature.com/articles/s4159…
ORR 31%,⏫historical control of pembro monotherapy (~17%)
Details below:

NEW online & being presented this afternoon at the #AACR24 poster session: A personalised DNA #CancerVaccine + anti-PD1 was safe & led to encouraging clinical efficacy in patients with advanced #LiverCancer Mark Yarchoan Johns Hopkins Kimmel Cancer Center Niranjan Sardesai #HCC nature.com/articles/s4159…

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers | MedPage Today. Exciting news for GI cancers including BTC and CRC ⁦Cholangiocarcinoma Foundation⁩ ⁦ENSCCA_2020⁩ ⁦MD Anderson Cancer Center⁩ medpagetoday.com/hematologyonco…

Just out: Nat’l Estimates of Participation of #Cancer Pts in #cancerresearch has ⬆️ from <5% to 7.1%; NCI designated cancer centers ⬆️ to 21.6%. We can still do better 💪🏻! #CommissiononCancer | ascopubs.org/doi/full/10.12… Journal of Clinical Oncology @asco Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center #PatientCare …

P1 trial of TPST1120 (PPARα antagonist)
pubmed.ncbi.nlm.nih.gov/38551394/
➡️Metabolic target directly impairs tumor growth & reprograms TME
➡️SD with monotherapy & responses in combo w/ PD1 (2PR w/ prior anti-PD1)
➡️P2 ongoing (TSPT1120+bev/ateo) in #HCC

Our latest manuscript describes efforts to define endogenous T cell responses to the fusion driver characteristic of fibrolamellar carcinoma (FLC). Outcomes for FLC patients are poor, so new therapies are urgently needed. cell.com/cell-reports-m… 🧵(1/15)

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] Kabir Mody et al. Mark Yarchoan JCO Precision Oncology ascopubs.org/doi/full/10.12… #hpbcsm #PrecisionMedicine

Ipi/nivo in 1L #HCC is positive! (CheckMate-9DW study). Excited to see the full data soon...
news.bms.com/news/corporate…

Cabozantinib/atezo vs sorafenib vs Cabo for HCC
The Lancet Gastroenterology & Hepatology
doi.org/10.1016/S2468-…
🔎COSMIC-312 phs-3: final results
👉 mPFS: 6.9 vs 4.3 vs 5.8 mo
👉no OS benefit for IO-combination
👉Consistent efficacy for cabo in 1st & 2nd line HCC
ESMO - Eur. Oncology EASLnews ILCA…

Adjuvant sintilimab in resected high-risk HCC
Nature Medicine
doi.org/10.1038/s41591…
🔎Phs 2 🇨🇳
👉Benefit for HCC w/ MVI, mRFS, 27.7 vs 15.5
🧐What is the role for Bev in adj. setting?
👉More to come soon... field is moving in HCC
ESMO - Eur. Oncology EASLnews ILCA #livertwitter

Anti-competitive practices of 10X genomics have forced Nanostring into chapter 11 restructuring. 10x has initiated litigation against not only Nanostring but also Vizgen, Curio Biosciences and Parse Biosciences. See below for more information:
(genengnews.com/topics/biopers…)…